Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a subtype of Hodgkin lymphoma (HL), and is a rare disease manifestation in the adrenal gland, which is difficult to be diagnosed and treated. In the present study, we report a case of primary adrenal NLPHL in a 36-year-old male patient. The patient was without specific clinical signs and the definitive diagnosis was achieved by histolog...

BACKGROUND Bleomycin hydrolase (BLMH), an enzyme that inactivates bleomycin, may be a potential candidate that could influence pulmonary function in ABVD (doxorubicin, bleomycin, vinblastin, dacarbasine)-treated Hodgkin lymphoma (HL) patients. PATIENTS AND METHODS We hypothesized that the BLMH gene SNP A1450G (rs1050565) influences BLMH activity and late pulmonary toxicity. St. George Respira...

Therapy of advanced Hodgkin lymphoma (HL) is a rapidly changing field due to a lot of currently emerging data. Treatment approaches are presently based on either the Kairos principle of giving aggressive therapy upfront and considering de-escalation of therapy if the interim PET/CT is negative or the Chronos principle of starting with ABVD followed by escalation of therapy for patients with pos...

Interdigitating dendritic cell sarcoma (IDCS) is a very rare and aggressive neoplasm that arises from antigen presenting cells. IDCS usually involves lymph nodes; however, extra-nodal involvement has also been reported. Because a consistent standard therapy for IDCS has not been established to date, we report a case of the successful treatment of disseminated IDCS using ABVD chemotherapy (doxor...

Interdigitating dendritic cell sarcoma (IDCS) is a rare and aggressive neoplasm that is thought to arise from dendritic cells. This disease usually involves the lymph nodes and, rarely, extra-nodal sites. We report a 62-year-old man presenting skin nodules in the head, body, and extremities, as well as bone marrow involvement. Morphologic analysis of a biopsied specimen from the skin lesion was...

BACKGROUND AND OBJECTIVE Patients affected by Hodgkin's disease (HD) in pathologic stage IA-IIA have a strong possibility of remission and long-term survival when treated with radiotherapy to extended fields. However, 20-30% of cases relapse in the five years following treatment and consequently need further therapy. This study examines the occurrence of relapse and other complications in patie...

In “The Case for Combined-Modality Therapy for LimitedStage Hodgkin’s Disease,” [1] authors Hill-Kayser, Plastaras, Tochner, and Glatstein provide a detailed, instructive, and informative discussion of the insights into the management of Hodgkin’s lymphoma that can be derived from the recently published National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)/Eastern Cooperative Onc...

Resumen El ictus representa la principal causa de dependencia funcional en poblacion adulta portuguesa. Objetivo Analizar el impacto rehabilitacion estado y las actividades basicas vida diaria (ABVD), tras 8 semanas sufrir un ictus, una ancianos del noroeste Portugal. Metodologia Estudio observacional, longitudinal retrospectivo. Los pacientes fueron agrupados 3 grupos acuerdo con tratamiento r...